Beta Bionics Launches $125M Stock Offering to Fund Mint Commercialization
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Beta Bionics announced a proposed underwritten public offering of common stock, upsized to $150 million from $125 million, with a 30-day underwriter option for an additional $18.75 million, which the update specifies covers 1.3 million additional shares. The offering is priced at $17.25 per share and comes off the shelf registration filed in February 2026, just one day after FDA clearance of its Mint patch pump. Proceeds are earmarked for Mint commercialization, manufacturing expansion, R&D, and working capital. The offering represents roughly 14% of the company's current market cap, a meaningful dilution for existing shareholders. Shares fell 5.8% to $18.11 premarket.
Updated with a Dow Jones Newswires report · What changed
Updates
· Dow Jones Newswires — Beta Bionics priced the offering at $17.25 per share and upsized gross proceeds to $150 million from $125 million. The underwriter option covers 1.3 million additional shares. Shares fell 5.8% to $18.11 premarket.
At the time of this announcement, BBNX was trading at $17.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $865.2M. The 52-week trading range was $8.80 to $32.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.